Canaccord cuts Merit Medical stock price target on acquisition impact
Canaccord has lowered its price target for Merit Medical Systems (NASDAQ:MMSI) to $90 from $99, while maintaining a Buy rating, due to the impact of a recent $140 million acquisition. Despite the price target cut and an expected short-term EPS dilution, the acquisition is projected to contribute significantly to revenue and become accretive to non-GAAP EPS by 2027. This news comes amidst mixed analyst views, with BTIG reiterating a Buy rating, but Wells Fargo downgrading the stock to Equal Weight due to concerns over future guidance.
Merit Medical Systems (MMSI) Acquires View Point Medical for $140M
Merit Medical Systems (NASDAQ:MMSI) has acquired View Point Medical for approximately $140 million, including assumed liabilities, with an initial $90 million cash payment. The acquisition is expected to contribute $2M to $4M in revenue by the end of the year but will dilute non-GAAP and GAAP EPS in 2026 and 2027 before becoming accretive. This move follows recent strategic developments for MMSI, including a distribution agreement with Medtronic for a minimally invasive spinal pain system and the commercial release of a new esophageal stent.
SG Americas Securities LLC Takes Position in Merit Medical Systems, Inc. $MMSI
SG Americas Securities LLC has acquired a new stake of 17,433 shares in Merit Medical Systems, Inc. (NASDAQ:MMSI) during the fourth quarter, valued at approximately $1.54 million. Merit Medical Systems reported strong Q4 earnings, beating estimates with $1.04 EPS and a 10.9% year-over-year revenue increase, and provided positive FY 2026 guidance. Analysts currently give the stock a consensus "Moderate Buy" rating with an average target price of $101.25.
5 Best 52-Week Low NASDAQ Stocks to Buy Now
This article identifies five NASDAQ stocks that are trading at their 52-week lows and are considered potential buying opportunities. The article features Merit Medical Systems, Inc. (NASDAQ: MMSI) as one of these stocks, detailing its recent acquisition of View Point Medical and a distribution agreement with Medtronic, alongside the commercial release of a new esophageal stent. The full list and methodology are available in an extended version of the article.
MMSI SEC Filings - Merit Med Sys Inc 10-K, 10-Q, 8-K Forms
This page provides a comprehensive resource for investors to access Merit Medical Systems (MMSI) SEC filings, including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms. It highlights the detailed financial, operational, and risk information available in these documents, alongside AI-powered summaries and sentiment analysis for each filing. Recent filings include updates on reimbursement strategies for WRAPSODY, the acquisition of the C2 CryoBalloon device, Q3 2025 financial results, and changes in executive leadership.
Aberdeen Group plc Has $41.77 Million Stake in Merit Medical Systems, Inc. $MMSI
Aberdeen Group plc reduced its stake in Merit Medical Systems, Inc. by 8.6% in the fourth quarter, now holding 473,895 shares valued at $41.77 million. Despite this reduction, other large institutional investors like Wellington Management Group and Tudor Investment Corp significantly increased their positions, contributing to an overall institutional ownership of 99.66%. Analysts maintain a "Moderate Buy" rating for Merit Medical Systems with an average price target of $101.25, following the company beating its quarterly EPS estimates and reporting a 10.9% year-over-year revenue increase.
Merit Medical Systems, Inc. (NASDAQ:MMSI) Given Average Rating of "Moderate Buy" by Analysts
Merit Medical Systems, Inc. (NASDAQ:MMSI) has received an average rating of "Moderate Buy" from ten analysts, with a consensus one-year price target of $101.25. The company recently surpassed Q4 earnings and revenue expectations and has issued strong FY2026 guidance. Institutional investors hold a significant majority of the stock, and several analysts have recently updated their ratings and price targets for MMSI.
Merit Medical Acquires View Point Medical, Inc., expanding the Merit Therapeutic Oncology Portfolio
Merit Medical Systems, Inc. has acquired View Point Medical, Inc. for $140 million, significantly expanding its therapeutic oncology portfolio for breast and soft tissue tumors. This acquisition introduces View Point's ultrasound-enhanced OneMark Detection Imaging System and Tissue Markers, complementing Merit's existing SCOUT platform. The integration aims to provide more comprehensive localization options during initial diagnostic biopsies, potentially reducing the need for separate procedures before surgery.
Merit Medical acquires View Point to expand oncology portfolio
Merit Medical Systems (MMSI) has acquired View Point Medical, Inc. for approximately $140 million, integrating View Point's FDA-cleared OneMark Detection Imaging System and related assets into its oncology portfolio. This strategic acquisition aims to enhance Merit Medical's offerings in wire-free breast and soft tissue tumor localization. The deal is expected to contribute $2 million to $4 million in revenue by the end of 2026 and become accretive to non-GAAP earnings per share by 2027.
Wilson Sonsini Advises View Point Medical on Acquisition by Merit Medical
Wilson Sonsini Goodrich & Rosati advised View Point Medical, Inc. on its acquisition by Merit Medical Systems, Inc. The transaction, valued at approximately $140 million including liabilities, expands Merit's portfolio of therapeutic oncology products. View Point, known for its OneMark® Detection Imaging System and Tissue Markers, will now operate as a wholly owned subsidiary of Merit.
Merit Medical Systems to Announce First Quarter 2026 Results on April 30, 2026
Merit Medical Systems, Inc. (NASDAQ: MMSI) announced it would release its financial results for the first quarter ended March 31, 2026, after the stock market closes on Thursday, April 30, 2026. The company will also host an investor conference call on the same day at 4:30 p.m. Eastern Time. Merit Medical Systems specializes in developing, manufacturing, and distributing proprietary medical devices for various interventional and diagnostic procedures.
Merit Medical Systems to Announce Q1 2026 Earnings
Merit Medical Systems, a global leader in healthcare technology, is set to release its Q1 2026 financial results on Thursday, April 30, 2026, after market close, followed by an investor conference call. This announcement is crucial for investors and analysts to assess the company's financial health, operational performance, and market conditions within the medical device industry. The company, founded in 1987, specializes in developing and distributing proprietary medical devices for various interventional procedures.
Merit Medical Systems to Announce First Quarter 2026 Results on April 30, 2026
Merit Medical Systems, Inc. (NASDAQ: MMSI) announced it will release its financial results for the first quarter ended March 31, 2026, after the stock market closes on April 30, 2026. The company will also host an investor conference call on the same day at 4:30 p.m. Eastern Time to discuss the results. Interested parties can pre-register for the call or access a live webcast and slide deck via links provided by the company.
Merit Medical schedules April 30 call after first-quarter results
Merit Medical Systems (NASDAQ: MMSI) will release its first-quarter 2026 financial results after market close on Thursday, April 30, 2026. The company will host an investor conference call the same day at 4:30 p.m. ET, with a live webcast and slide deck available on its website. This announcement follows several recent positive developments for Merit Medical, including acquisitions, product launches, and partnerships, though past news events have often been followed by negative short-term stock reactions.
Merit Medical acquires View Point for $140M
Merit Medical Systems has acquired View Point Medical for $140 million to bolster its oncology portfolio. View Point specializes in tissue localization devices for biopsies and cancer surgeries, complementing Merit's existing offerings. The deal includes an upfront payment of $90 million, with an additional $50 million to be paid in two installments over the next two years.
Merit Medical Systems (NASDAQ:MMSI) Given "Buy" Rating at Needham & Company LLC
Needham & Company LLC has reissued a "Buy" rating for Merit Medical Systems (NASDAQ:MMSI), setting a price target of $101.00, which suggests a 48% upside. The medical instruments supplier exceeded quarterly earnings expectations with $1.04 EPS versus $0.96 and reported revenue of $393.9M, a 10.9% year-over-year increase. Analyst sentiment for MMSI is largely positive, with a consensus price target of $101.25, and institutional investors holding approximately 99.66% of the company's stock.
Merit Medical Systems, Inc. to Announce Q1 2026 Financial Results and Host Investor Conference Call on April 30
Merit Medical Systems, Inc. will release its Q1 2026 financial results after the stock market closes on April 30, 2026, and host an investor conference call on the same day at 4:30 p.m. Eastern Time. The company, founded in 1987, specializes in medical devices for interventional procedures, with a global workforce of approximately 7,600. Investors are required to pre-register for the call, and a live webcast will also be available on Merit Medical's website.
Merit Medical Systems: $140 Million Acquisition Of View Point Medical Expands Oncology Portfolio
Merit Medical Systems has acquired View Point Medical, Inc. for approximately $140 million, paying $90 million upfront and two $25 million payments in subsequent years. This acquisition expands Merit's therapeutic oncology portfolio, especially in wire-free breast localization, with View Point's OneMark Detection Imaging System complementing Merit's SCOUT platform. Merit projects the acquisition to contribute $2 million-$4 million in revenue for the rest of 2026 and $14 million-$16 million in 2027, with anticipated long-term accretion to non-GAAP earnings.
Merit Medical (NASDAQ: MMSI) expands oncology line with $140M View Point purchase
Merit Medical Systems (NASDAQ: MMSI) has acquired View Point Medical for approximately $140 million, expanding its therapeutic oncology portfolio with the OneMark Detection Imaging System and OneMark Tissue Markers. The acquisition is expected to contribute $2–$4 million in revenue for the remainder of 2026, with a $0.05 dilution to non-GAAP EPS, while projected to be accretive to non-GAAP EPS by 2027 with $14–$16 million in revenue. This strategic move aims to strengthen Merit's position in wire-free, non-radioactive tumor localization, complementing its existing SCOUT platform.
Discipline and Rules-Based Execution in MMSI Response
This article provides an AI-driven analysis of Merit Medical Systems Inc. (NASDAQ: MMSI), highlighting near-term strong sentiment potentially challenging persistent mid and long-term weakness. It offers distinct trading strategies—Position, Momentum Breakout, and Risk Hedging—along with multi-timeframe signal analysis, and lists key support and resistance levels. The report emphasizes elevated downside risk due to the absence of long-term support signals.
New Utah sports partnership leaves Merit Medical Systems stock consolidating amid persistent bearish momentum
Merit Medical Systems (MMSI) stock is consolidating below major moving averages despite a new partnership with Real Salt Lake and Utah Royals FC. Technical indicators suggest persistent bearish momentum, with the price expected to trade between $67.00 and $71.00 this week. Investors are advised to monitor upcoming product developments as a potential catalyst for price movement, as there's a low probability of a sustained price increase.
The Bull Case For Merit Medical Systems (MMSI) Could Change Following Medtronic ViaVerte Distribution Deal - Learn Why
Merit Medical Systems (MMSI) recently secured a distribution agreement with Medtronic for its ViaVerte system, which treats chronic lower back pain. This deal expands Merit's access to Medtronic's pain management network and strengthens its position in outpatient spine interventions. While promising, the company's investment narrative still heavily relies on securing timely reimbursement for other key products like WRAPSODY CIE.
Fort Washington Investment Advisors Inc. OH Acquires 19,305 Shares of Merit Medical Systems, Inc. $MMSI
Fort Washington Investment Advisors Inc. OH has increased its stake in Merit Medical Systems, Inc. by 6.4%, purchasing an additional 19,305 shares to bring its total holdings to 321,023 shares valued at approximately $28.3 million. Merit Medical (NASDAQ: MMSI) recently exceeded quarterly earnings expectations with $1.04 EPS on $393.94 million in revenue, leading to a "Moderate Buy" consensus rating from analysts with an average target price of $101.25. Institutional investors collectively own 99.66% of the company's stock, indicating strong institutional confidence.
Merit Medical Systems (NASDAQ:MMSI) Upgraded to "Strong-Buy" at Wall Street Zen
Wall Street Zen has upgraded Merit Medical Systems (NASDAQ:MMSI) to a "Strong-Buy" rating, citing increased analyst confidence. This upgrade follows the company's strong financial performance, including exceeding Q4 2025 earnings and revenue estimates and providing positive FY2026 guidance. The stock currently holds a "Moderate Buy" consensus rating among analysts with an average target price of $101.25.
Why is Merit Medical (MMSI) down 14% since last earnings report?
This article analyzes why Merit Medical (MMSI) stock has dropped 14% since its last earnings report. It highlights mixed Q4 2023 results where revenue beat expectations but earnings per share missed consensus estimates. The article also points to the company's 2024 guidance, which was below analyst forecasts, as a key factor in the stock's decline.
Vanguard disaggregates holdings; reports 0 shares in Merit Medical (MMSI)
The Vanguard Group filed an amended Schedule 13G/A, reporting 0 shares and 0% beneficial ownership of Merit Medical Systems Inc. common stock, attributed to an internal realignment. This change means certain Vanguard subsidiaries will now report their holdings separately, in reliance on SEC Release No. 34-39538. The filing clarifies that the adjustment reflects a change in reporting mechanics rather than a market sale by Vanguard, advising investors to monitor future filings from these disaggregated subsidiaries.
Medtronic and Merit Medical Systems distribution agreement for new, ViaVerte basivertebral nerve ablation system
Medtronic has entered a distribution agreement with Merit Medical Systems to offer the ViaVerte basivertebral nerve ablation (BVNA) system. This FDA-cleared system is designed for precise targeting of the basivertebral nerve to treat chronic vertebrogenic lower back pain. This collaboration expands Medtronic's pain intervention portfolio and enhances an existing relationship between the two companies.
Has Merit Medical Systems (MMSI) Become More Attractive After Its Recent Share Price Slide
Merit Medical Systems (MMSI) has experienced a significant share price decline, making investors question its current valuation. A Discounted Cash Flow (DCF) analysis suggests the stock is undervalued by 17.4% at approximately $67.55 per share, indicating a potential intrinsic value of $81.76. However, its P/E ratio of 31.24x is higher than the industry average and Simply Wall St's "Fair Ratio" of 24.94x, suggesting it might be overvalued based on earnings.
MDT Broadens Partnership With Merit to Provide ViaVerte: Will Shares Rise?
Medtronic (MDT) has announced a new distribution partnership with Merit Medical Systems (MMSI) to offer the FDA-cleared ViaVerte system, a minimally invasive basivertebral nerve ablation (BVNA) device for chronic lower back pain. This collaboration aims to expand Medtronic's pain intervention portfolio, addressing a growing demand in a market projected to reach $1.56 billion by 2033. Despite a slight initial dip in shares, the move is expected to positively impact MDT stock, complementing Medtronic's recent FDA approval for expanded use of its OmniaSecure defibrillation lead.
Medtronic (MDT) Partners with Merit Medical to Distribute Innovative Pain System
Medtronic (MDT) has partnered with Merit Medical Systems to distribute the FDA-cleared ViaVerte system, a minimally invasive solution for chronic vertebrogenic lower back pain. This collaboration aims to enhance Medtronic's product offerings and reinforce its leadership in the healthcare sector. The company shows strong financial health with robust revenue growth, efficient operations, and a stable market position, despite its Altman Z-Score indicating some financial stress.
Merit Medical stock gains exclusive distribution deal with Medtronic
Merit Medical Systems, Inc. (MMSI) announced an exclusive distribution agreement with Medtronic for the ViaVerte system, an FDA-cleared treatment for chronic lower-back pain. This deal positions Merit Medical in a growing basivertebral nerve ablation market, despite the company's recent stock performance near 52-week lows. Analysts maintain varied ratings, with some adjusting price targets while reiterating confidence in the company's product portfolio.
Medtronic and Merit Medical Systems enter into agreement to offer new, FDA-cleared ViaVerte™ system, a basivertebral nerve ablation treatment for chronic vertebrogenic lower-back pain
Medtronic has announced a distribution agreement with Merit Medical Systems to offer the FDA-cleared ViaVerte™ system, a minimally invasive and implant-free basivertebral nerve ablation (BVNA) system. This system is designed for precise basivertebral nerve targeting to treat chronic vertebrogenic lower back pain. The agreement expands Medtronic's pain interventions portfolio and strengthens its relationship with Merit Medical Systems.
New back-pain treatment will reach Medtronic customers later this year
Medtronic has entered into a distribution agreement with Merit Medical Systems to offer the FDA-cleared ViaVerte™ system, a basivertebral nerve ablation treatment for chronic vertebrogenic lower-back pain. This minimally invasive, implant-free system will be available later in 2026 and expands Medtronic's pain interventions portfolio. The agreement strengthens an existing relationship between the two companies and aims to provide more treatment options for patients suffering from chronic pain.
Congress Asset Management Co. Buys 184,738 Shares of Merit Medical Systems, Inc. $MMSI
Congress Asset Management Co. increased its stake in Merit Medical Systems, Inc. (NASDAQ:MMSI) by 27.5% in the fourth quarter, acquiring an additional 184,738 shares. The firm now owns 857,639 shares of the medical instruments supplier, valued at $75.59 million. Other institutional investors have also adjusted their positions, and analysts currently rate MMSI as a "Moderate Buy" with a consensus target price of $103.33.
A Look At Merit Medical Systems (MMSI) Valuation After The Recent Share Price Pullback
Merit Medical Systems (MMSI) has seen a recent share price pullback, with the stock declining significantly over the past month and year-to-date. Despite trading at a higher Price-to-Earnings ratio of 30.9x compared to industry averages, a Discounted Cash Flow model suggests the company is 18.2% undervalued. This analysis highlights mixed signals regarding MMSI's valuation, presenting a potential buying opportunity for some while cautioning about the P/E premium.
A Look At Merit Medical Systems (MMSI) Valuation After The Recent Share Price Pullback
Merit Medical Systems (MMSI) has experienced a recent share price pullback, with declines over the past day, week, month, and year. Despite a P/E ratio of 30.9x suggesting overvaluation compared to industry averages and its own fair P/E, a Discounted Cash Flow (DCF) model indicates the stock is 18.2% undervalued. Investors are presented with mixed signals regarding whether the current dip represents a buying opportunity.
Merit Medical Systems stock hits 52-week low at $67.33
Merit Medical Systems (MMSI) stock recently fell to a 52-week low of $67.33, marking a 32.84% decline over the past year despite recent positive financial reports. While the company's Q4 2025 revenue and EPS surpassed estimates and 2026 guidance exceeded expectations, analyst ratings have been mixed, with some downgrades and price target adjustments. InvestingPro suggests the stock may be undervalued, presenting a potential opportunity for investors.
35,000,000 Shares in Merit Medical Systems, Inc. $MMSI Acquired by Tudor Investment Corp ET AL
Tudor Investment Corp ET AL has acquired a significant new stake of 35,000,000 shares in Merit Medical Systems, Inc. (NASDAQ:MMSI), valued at approximately $2.91 billion. This acquisition makes Merit Medical Systems the 13th largest holding in Tudor's portfolio, representing 1.8% of its total investments, and brings Tudor's total ownership to 59.03% of the company. Merit Medical Systems recently exceeded quarterly earnings estimates and provided optimistic FY2026 guidance, maintaining a "Moderate Buy" consensus analyst rating.
JPMorgan Chase & Co. Purchases 64,920 Shares of Merit Medical Systems, Inc. $MMSI
JPMorgan Chase & Co. has increased its stake in Merit Medical Systems, Inc. (NASDAQ:MMSI) by 7.6%, acquiring 64,920 additional shares, bringing its total to 917,122 shares valued at approximately $76.3 million. Several other institutional investors also substantially boosted their holdings, leading to a total institutional ownership of 99.66%. Merit Medical Systems recently outperformed quarterly earnings estimates and provided optimistic FY2026 guidance, while analysts maintain a "Moderate Buy" rating for the stock.
MMSI Introduces the Resilience TTS Stent for Treating Esophageal Fistulas and Strictures
Merit Medical Systems (MMSI) has launched its Resilience Through-the-Scope (TTS) Esophageal Stent in the U.S. designed for esophageal fistulas and malignant strictures. This stent aims to address limitations of existing TTS stents with features like anti-migration technology, unique sizing, and easier deployment. The company anticipates this innovation will strengthen its market position and drive revenue growth, despite a recent 15.9% decline in its stock over the past six months.
Merit Medical Systems launches Resilience Through-the-Scope Esophageal Stent
Merit Medical Systems has announced the introduction of its new Resilience Through-the-Scope Esophageal Stent. This new medical device is designed to improve the ease of deployment and patient outcomes for esophageal procedures. The company emphasized its continued investment in innovative technologies for minimally invasive care.
Merit Medical Launches the Resilience Through-the-Scope Esophageal Stent
Merit Medical Systems, Inc. has launched the Resilience Through-the-Scope (TTS) Esophageal Stent in the US. This new stent addresses the needs of patients with esophageal fistulas and malignant strictures, featuring an anti-migration design, a single-handed deployment system, and unique size options. The company emphasizes its commitment to innovation in the rapidly growing TTS stent-technology market.
New esophageal stent uses anti-migration design for cancer-related narrowing
Merit Medical (NASDAQ: MMSI) has commercially launched its Resilience Through-the-Scope (TTS) Esophageal Stent in the U.S. This new stent is designed to treat esophageal fistulas and strictures caused by malignant tumors, featuring proprietary anti-migration flanges for secure placement and a single-handed deployment system for precision. The Resilience stent also offers unique size options (14x50, 17x50, and 20x50 mm) to address various clinical needs and overcome common challenges with stent migration and placement.
ArrowMark Colorado Holdings LLC Sells 27,942 Shares of Merit Medical Systems, Inc. $MMSI
ArrowMark Colorado Holdings LLC reduced its stake in Merit Medical Systems by 4.3%, selling 27,942 shares, while other institutional investors like Wellington Management, Thrivent, Greenhouse Funds, and Bessemer Group significantly increased their holdings. Merit Medical Systems reported an earnings beat with a Q3 EPS of $1.04 and revenue of $393.94 million, exceeding analyst expectations. The company also provided strong FY2026 guidance and maintains a "Moderate Buy" analyst consensus rating with a target price of $103.33.
Will Wells Fargo’s Downgrade and Selling Wave Change Merit Medical Systems’ (MMSI) Narrative
Wells Fargo recently downgraded Merit Medical Systems (MMSI), leading to institutional selling despite the company's solid underlying operations and financial health. The downgrade primarily impacts sentiment rather than core business fundamentals, as the company continues to show revenue and earnings growth with positive 2026 guidance. This situation presents a contrast between market sentiment and business execution, prompting investors to consider if current pricing reflects known risks like delayed WRAPSODY reimbursement and higher spending.
Capital World Investors Raises Stock Position in Merit Medical Systems, Inc. $MMSI
Capital World Investors increased its stake in Merit Medical Systems (MMSI) by 43.3% to 171,960 shares, now valued at approximately $14.31 million. Other institutional investors also significantly increased their holdings, bringing total institutional ownership to ~99.66%. Despite reporting strong quarterly earnings and providing positive FY2026 guidance, MMSI's stock is currently trading near a one-year low with a market cap of $4.05 billion and a consensus target price of $103.33.
Assessing Merit Medical Systems (MMSI) Valuation After Recent Share Price Weakness
Merit Medical Systems (MMSI) has experienced recent share price weakness, with negative returns over the past week, month, three months, and year-to-date. Despite this, its five-year return shows resilience. The stock's P/E ratio of 32.4x suggests it is overvalued compared to peers and industry averages, though a Discounted Cash Flow (DCF) model indicates it might be trading below its estimated fair value.
Here’s Why Including Merit Medical Shares in Your Investment Portfolio Makes Sense Now
Merit Medical Systems, Inc. (MMSI) is poised for continued growth driven by its strong medical device pipeline, particularly in cardiovascular and therapeutic products, and strategic acquisitions. Despite recent stock drops and challenges like tariffs and economic pressures in China, analysts are optimistic about its future earnings. The company anticipates a 9.5% growth rate over the next five years, supported by innovation and expanding global procedure volumes.
Here's Why You Should Add Merit Medical Stock to Your Portfolio Now
Merit Medical Systems (MMSI) is a strong investment due to its robust product portfolio, significant growth in cardiovascular and peripheral intervention devices, and continuous innovation through R&D and strategic acquisitions. Despite challenges like tariffs and pressures in the OEM business and the China market, the company exhibits a positive earnings outlook and is well-positioned for future growth.
Greenhouse Funds LLLP Boosts Holdings in Merit Medical Systems, Inc. $MMSI
Greenhouse Funds LLLP significantly increased its stake in Merit Medical Systems, Inc. ($MMSI) by 48.3%, now holding 871,927 shares valued at $72.57 million. This move makes MMSI the fund's 20th largest position, accounting for approximately 2.7% of its portfolio. The medical instrument supplier recently reported strong quarterly earnings, beating analyst expectations with an EPS of $1.04 and revenue of $393.94 million, and set optimistic FY2026 guidance.
